US Court Grants MGI s Motion to Amend in Suit Against Illumina
USA - English
Share this article
Share this article
SAN FRANCISCO, Feb. 23, 2021 /PRNewswire/ A judge in the U.S. District Court for the Northern District of California has granted MGI s motion for leave to amend to add a new inequitable conduct defense of patent infringement lawsuit that Illumina filed against MGI in February 2020 (Case No. 20-cv-01465).
During this patent prosecution process, MGI alleges that Illumina intentionally withheld or failed to disclose a reference to a paper by Terez Kovacs and Laslo Otvos ( Kovacs )
[1]. MGI asserts that the Kovacs reference is material, both because it discloses the same methodology that two of the inventors of the 7,541,444 patent used to convert nucleosides to nucleotides and also because it provides a motivation for a person of ordinary skill in the art ( POSITA ) to convert nucleosides to nucleotides.
Share this article
Share this article
STOCKHOLM, Feb. 10, 2021 /PRNewswire/ MGI Tech Co., Ltd. ( MGI ) s high-throughput gene sequencer has helped the regions throughout Sweden greatly improve their COVID-19 testing capabilities from the laboratory at the National Pandemic Center located in Karolinska Institute (KI). Sweden s STV News, the national public television, recently reports that only one percent (1%) of the positive COVID-19 samples have been currently sequenced in Sweden and main regions in the country have been commissioned to increase the figure to ten percent (10%). The KI laboratory is one of the few highly specialized laboratories in Sweden that can perform whole-genome sequencing and COVID-19 monitoring. The high-throughput gene sequencers and automation system used in this laboratory are from MGI.